Retatrutide, a experimental dual agonist of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) target, is showing promising data in early clinical assessments . Ongoing inquiry https://bookmarks-hit.com/story25474161/retatrutide-emerging-studies-and-potential-clinical-applications